Peringatan Keamanan

If radiation overdose occurs, patients should be advised to drink plenty of water and to void frequently to increase the rate of elimination of the radionuclide.L16393 In certain cases, it may be appropriate to administer a diuretic.L16393

Copper oxodotreotide Cu-64

DB15873

small molecule approved

Deskripsi

Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over 68Ga-labeled somatostatin analogs for positron emission tomography (PET).A220348 Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution.A220348 Further studies should be performed to compare the two tracers.

Further, PET using Copper Cu 64 dotatate has been found to perform better than the current gold standard of single-photon emission computed tomography (SPECT) using 111In-DTPA-octreotide.A220348 In a head-to-head trial, the former tracer detected twice as many lesions as the latter.A220348

Struktur Molekul 2D

Berat 1497.55
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of Copper Cu 64 is 12.7 hours.[L16393]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Radioactivity can be identified in the kidney, liver, adrenal glands, spleen, and pituitary glands 1-3 hours after copper Cu 64 dotatate is administered.L16393

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

16% - 40% of the original radioactivity was detected in urine 6 hours after the intravenous administration of a single dose.L16393

Interaksi Makanan

1 Data
  • 1. Take with fluids. Patients should remain well hydrated before and after imaging with copper Cu 64 dotatate to limit radiation exposure.

Interaksi Obat

5 Data
Octreotide The therapeutic efficacy of Octreotide can be decreased when used in combination with Copper oxodotreotide Cu-64.
Vapreotide The therapeutic efficacy of Vapreotide can be decreased when used in combination with Copper oxodotreotide Cu-64.
Pasireotide The therapeutic efficacy of Pasireotide can be decreased when used in combination with Copper oxodotreotide Cu-64.
Lanreotide The therapeutic efficacy of Lanreotide can be decreased when used in combination with Copper oxodotreotide Cu-64.
Somatostatin The therapeutic efficacy of Somatostatin can be decreased when used in combination with Copper oxodotreotide Cu-64.

Target Protein

Somatostatin receptor type 2 SSTR2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25952736
    Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Rasmussen P, Elema D, von Benzon E, Hojgaard L, Kjaer A: 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. J Nucl Med. 2015 Jun;56(6):847-54. doi: 10.2967/jnumed.115.156539. Epub 2015 May 7.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Detectnet
    Injection, solution • 1.0 mCi/1mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul